Savior Lifetec Corp. · TPEX:4167
Savior Lifetec — 9M23 Earnings Presentation
22 slides from Savior Lifetec's earnings presentation, Nov 22, 2023
Slide 1: Investor Conference
Investor Conference Nov 22, 2023
Slide 2: Disclaimer
DISCLAIMER This presentation has been provided by Savior Lifetec Corporation (SLC) for informational purposes only. It is not an offer to buy or sell or a solicitation of an offer to buy or sell any security issued by SLC or other parties. This presentation may contain forward-looking statements whi
Slide 3: SLC Group Overview, Financial Overview, Company Strategy & Vision
SLC Group Overview • Company Organization & Industry Position Financial Overview • 9M23 Company Strategy & Vision • Penem Marketing Strategy • Company Vision 3
Slide 4: SLC Group Overview, Financial Overview, Company Strategy & Vision
SLC Group Overview • Company Organization & Industry Position Financial Overview • 9M23 Company Strategy & Vision • Penen Marketing Strategy • Company Vision 4
Slide 5: SLC Pharma - Industry Position in Taiwan and the World
SLC Pharma- Industry Position in Taiwan and the World Taiwan's First and the Only Vertically-Integrated Pharma Company: Sterile API + Finished Dosage Form (Injectables) + Self-Owned ANDA Taiwan’s Largest Injectable Drug Manufacturer and Exporter to the US Market Top 3 Carbapenem Injectable Drug Supp
Slide 6: SLC Group – Multiple Profit Models
SLC Group – Multiple Profit Models SLC Pharma (4167 TT) • Established Since Jan. 30, 2004 / IPO Time (TPEx): Sep. 8, 2015 • Business Focus: Carbapenem API, Injectables, and CDMO SLC BioPharm • • Established Since Feb. 8, 2022 • Business Focus: Specialty Pharma Products (API, Finished Product, and CD
Slide 7: SLC Group – Key Personnel
SLC Group – Key Personnel SLC BioPharm Y.F. Chen, Compliance/ Process Chairman & 25+ Yrs General Manager & CTO of ScinoPharm Ph. D Development/ Product Strategy General Manager SLC Pharma Production/ Compliance/ Product Freon Chen 25+ Yrs Vice President & CMO of ScinoPharm General Manager Strategy S
Slide 8: SLC Pharma – Continuous Improvement of Process
SLC Pharma – Continuous Improvement of Process The 2nd Generation Process Successfully Increases Ertapenem Capacity and Simultaneously Fulfill the Company’s ESG Goal Advantges of the 2nd Generation Process： • Shorten the Process Cycle Time, Increase the Batch Size, and Reduce the Carbon Emission • R
Slide 9: SLC Group Overview, Financial Overview, Company Strategy & Vision
SLC Group Overview • Company Organization & Industry Position Financial Overview • 9M23 Company Strategy & Vision • Penen Marketing Strategy • Company Vision 9
Slide 10: 9M Combined Income Statement
9M Combined Income Statement (NT$mn) 9M23 9M22 Net Sales 732 1,012 COGS 644 911 Gross Profit 88 101 Gross Margin 12% 10% Operating Expense 170 174 Operating Income (82) (73) Operating Margin (11%) (7%) Non-Op Income (Expense) 66 151 Net Income (16) 77 Net Margin (2%) 8% EPS (NT$) (0.04) 0.24 10
Slide 11: 3Q Combined Income Statement
3Q Combined Income Statement (NT$mn) 3Q23 2Q23 3Q22 Net Sales 287 223 348 COGS 281 194 304 Gross Profit 6 29 44 Gross Margin 2% 13% 12% Operating Expense 55 58 56 Operating Income (49) (29) (12) Operating Margin (17%) (13%) (4%) Non-Op Income 32 33 145 (Expense) Net Income (17) 4 133 Net Margin (6%)
Slide 12: The Summary of Combined Balance Sheet
The Summary of Combined Balance Sheet (NT$mn) 2023/9/30 2022/12/31 2022/9/30 Cash and cash equivalents 1,130 1,086 1,089 Financial assets carried at 113 558 528 amortized cost – current Net accounts receivable 230 291 304 Inventory 合併綜合損益摘要 882 1,036 1,084 Property, plant and 893 1,005 1,047 equipme
Slide 13: Important Financial Indicators
Important Financial Indicators 2023/9/30 2022/12/31 2022/9/30 AR Turnover (Day) 99 113 108 Return on Assets (%) (0.28%) 0.5% 2.59% Return on Equity (%) (0.57%) 1.09% 3.07% 合併綜合損益摘要 Debt Ratio (%) 11.08% 23.63% 23.18% 13
Slide 14: SLC Group Overview, Financial Overview, Company Strategy & Vision
SLC Group Overview • Company Organization & Industry Position Financial Overview • 9M23 Company Strategy & Vision • Penen Marketing Strategy • Company Vision 14
Slide 15: Carbapenem is the Last Line Antibiotics
Carbapenem is the Last Line Antibiotics Gram Positive Cocci Gram Negative Bacilli E. Coli, Klebsiella Anaerobes MRSA MSSA Streptococci Proteus Pseudomonas ESCAPPM Amoxicillin (Penicillin) Amoxicillin-Clavulanate Amoxicillin-Clavulanate (Penicillin + BLI) (Penicillin + BLI) Piperacillin-Tazobactam Pi
Slide 16: Vertically Integrated Specialty Pharma Model
Vertically Integrated Specialty Pharma Model 1 2 3 4 Chemical Synthesis Aseptic API Process Aseptic Filling Line Market (SLC Label) + Crude API API(Sterile Bulk) Injectable (Sterile) Customer’s Filling Line Market Market (Customer’s Label) (Customer’s Label) 16
Slide 17: Core Technology: Aseptic Lyophilization
Core Technology: Aseptic Lyophilization From API Synthesis to Injectable Filling GMP “ Grade A “Aseptic Process API Manufacturing Aseptic API Process Aseptic Filling ▪ Chemical Synthesis ▪ Aseptic Lyophilization ▪ Injectable ▪ Sterile Dry Powder Raw Ertapenem Material API Ertapenem Filtration (Steri
Slide 18: Meropenem Global Market Growth
Meropenem Global Market Growth 2023 (Q1 MAT) Global Market Size: US$1,574mn +4.5% (Metric Tons) CAGR 250 200 142 152 151 150 120 Other 100 EU Market 50 68 70 62 US Market 57 22 23 25 24 0 2020 2021 2022 2023 Source: New Port, 2023 Q1 MAT 18
Slide 19: SLC's Market Share Increase vs Invanz's Supply Disruption
SLC’s Market Share Increase vs Invanz’s Supply Disruption 2023 (Q1 MAT) Global Market Size: US$283mn (Metric Tons) +0.9% 25 CAGR 20 15 11.2 6.2 6.2 6.2 Other 10 EU Market 2.3 2.4 2.4 2.4 US Market 5 5.9 5.7 5.9 6.1 0 2020 2021 2022 2023 Source: New Port, 2023 Q1 MAT 19
Slide 20: 2023-24 SLC's Ertapenem Market Share Expansion
2023-24 SLC’s Ertapenem Market Share Expansion
Slide 21: Company Vision
Company Vision Multiple Profit Models Ertapenem Market CDMO Expansion Specialty Product Novel Oral Penem 21
Slide 22: [email protected]